Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Front Immunol. 2021 Sep 8;12:741765. doi: 10.3389/fimmu.2021.741765. eCollection 2021.
The long-term impact of COVID-19 on transplant recipients remains unknown. We describe the case of a 30-year-old male kidney transplant recipient from Wuhan, China that was treated for severe COVID-19 in February 2020. He suffered an acute lung and renal injury and required systemic treatment including adjustment of his immunosuppressant regime. He was followed up to 1-year after discharge. No chronic lung fibrosis or deterioration of his pulmonary function was observed. Despite COVID-19 mediated damage to his renal tubular cells, no transplant rejection occurred. His immunological profile demonstrated both cellular anti-SARS-CoV-2 reactivity and specific humoral immunity, indicating that it is beneficial for the transplanted patients to be immunized with SARS-CoV-2 virus vaccine. This case will help guide clinical decision making for immunocompromised individuals that become infected with SARS-CoV-2.
新冠病毒（COVID-19）对移植受者的长期影响尚不清楚。我们描述了一例来自中国武汉的 30 岁男性肾移植受者，他于 2020 年 2 月因严重 COVID-19 接受治疗。他患有急性肺和肾损伤，需要全身治疗，包括调整免疫抑制剂方案。在出院后随访了 1 年。未观察到慢性肺纤维化或肺功能恶化。尽管 COVID-19 导致他的肾小管细胞受损，但没有发生移植排斥反应。他的免疫谱显示出针对 SARS-CoV-2 的细胞和体液免疫反应，这表明对移植患者接种 SARS-CoV-2 病毒疫苗是有益的。该病例将有助于为感染 SARS-CoV-2 的免疫功能低下个体的临床决策提供指导。
